Some positive news last week when the U.S. Food and Drug Administration (FDA) approved alectinib as an adjuvant treatment for ALK-positive non-small cell lung cancer.
‘Efficacy was demonstrated in a global, randomized, open-label trial (ALINA, NCT03456076) in patients with ALK-positive NSCLC who had complete tumor resection,’ the FDA said.
Ken Culver of ALK Positive, a patient and caregiver advocacy group in the US, said in a statement reported in MedPage Today, that: ‘The approval of Alecensa [alectinib] marks a pivotal moment for people newly diagnosed with early-stage ALK-positive lung cancer, who until now, were not able to receive ALK-specific therapy.’
‘With this significant advance, it is more important than ever that all patients diagnosed with early-stage lung cancer undergo testing for ALK and other recommended biomarkers to receive the treatment most appropriate for them.’
You can read more about this development here on the FDA website here.